Home › Samsung merger to drive growth in biopharmaceutical business
 

Keywords :   


Samsung merger to drive growth in biopharmaceutical business

2015-07-20 13:25:34| Semiconductors - Topix.net

Boosted by the successful merger of Samsung C&T and Cheil Industries last week, Samsung Group is geared to step up its efforts to expand and develop its biopharmaceutical business, seen by the group as a future growth engine. The $8 billion merger has tightened the group's grip on Samsung BioLogics, the conglomerate's biopharmaceutical business unit.

Tags: business drive growth samsung

Category:Electronics and Electrical

Latest from this category

All news
»
28.09Atlantic Tropical Weather Outlook
28.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Forecast Discussion Number 9
28.09Post-Tropical Cyclone Helene Graphics
28.09Post-Tropical Cyclone Helene Public Advisory Number 19
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 9
More »